2seventy bio (TSVT) has released an update to notify the public and investors about its officers.
On January 29, 2024, Nick Leschly resigned as president and CEO of the Company, effective at the Closing, to become Chair of the Board, succeeding Daniel Lynch. The Company entered into a Transition Agreement with Leschly, providing a $200,000 annual retainer and severance benefits. William D. Baird III was appointed as the new president and CEO, with an employment agreement detailing salary, bonus, and equity compensation. Victoria Eatwell was appointed as CFO with similar compensation arrangements. Both agreements include severance terms. Daniel Lynch announced his resignation from the Board effective at the 2024 annual meeting, while Philip Gregory, the chief scientific officer, will leave the Company to join Regeneron post-Asset Sale.
For further insights into TSVT corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.